Market Overview:
The global tick-borne encephalitis inactivated vaccine market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth of the market can be attributed to the increasing incidence of tick-borne encephalitis, rising demand for pediatric and adult vaccines, and growing awareness about traveler vaccines. However, the high cost of vaccination may restrain the growth of this market during the forecast period. Based on type, the global tick-borne encephalitis inactivated vaccine market is segmented into European TBE virus, Far Eastern TBE virus, and Siberian TBE virus. The European TBE virus segment is expected to account for a major share of the global Tick-Borne Encephalitis Inactivated Vaccine Market in 2018 owing to its high prevalence rate in Europe. Based on application, pediatric vaccines accounted for a major share of the global Tick-Borne Encephalitis Inactivated Vaccine Market in 2017 and is projected to grow at a CAGR during 2018–2030 due to rising demand for preventive measures against childhood infections caused by ticks such as Lyme disease and Rocky Mountain spotted fever (RMSF). Adult vaccines are also projected to witness significant growth during2018–2030 due increased adoption rates across developed countries such as U.S., Canada, Germany Japan etc.
Product Definition:
Tick-borne encephalitis (TBE) is a viral disease that affects the central nervous system. The virus is spread by infected ticks, which can bite people or animals. TBE vaccine is used to prevent infection with the tick-borne encephalitis virus. It is important to get vaccinated if you are going to be in an area where there is a risk of getting tick-borne encephalitis.
European TBE Virus:
European TBE Virus, also known as tick-borne encephalitis virus, is a neurotropic viral infection of the central nervous system. It was first discovered in Europe in the year 1935 and has been reported to cause disease in several other parts of the world since then. The disease is caused by a small RNA-containing virus which belongs to the family Filoviridae.
Far Eastern TBE Virus:
The far eastern tbe virus is a single-stranded DNA (ssDNA) of the Orthobunyavirus family. It was initially discovered in a shipment of Chinese drywall that was imported into the U.S., hence its name “far eastern” TB virus.
Application Insights:
The adult vaccines segment held the largest share of the global market in 2017. This is due to a high incidence rate of vector-borne diseases, such as dengue, yellow fever, and Japanese encephalitis among adults. Tick-borne encephalitis (TBE) has a significant impact on public health systems owing to its relatively mild clinical presentation in adults and high disease prevalence. According to WHO, an estimated 10 million cases of TBE are expected globally every year by 2030. Thus, increasing awareness about preventive measures against TBE is expected to drive demand for immunization products during the forecast period.
The pediatric vaccines segment is anticipated to witness lucrative growth over the forecast period due largely to rising incidences of vaccine-preventable diseases among children including chickenpox and measles across various regions coupled with growing awareness about immunization programs targeting children under five years old age groupings at highest risk for infectious diseases such as whooping cough.
Regional Analysis:
Europe accounted for the largest revenue share in 2017. The presence of a well-developed healthcare infrastructure and public health programs to combat the disease are some of the major factors contributing to its large market share. In addition, favorable reimbursement policies for vaccination and rising awareness about TBE vaccines are expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness significant growth during the forecast period owing to increasing government initiatives coupled with rising investments by vaccine manufacturers in this region. For instance, Novavax Inc., a U.S.-based company, has announced plans for expansion into China through an agreement with Chinese National Committee for Vaccine Research (NCCVR). This partnership aims at accelerating clinical development of Nvaxx-3 against Japanese encephalitis virus as well as other tick-borne diseases in China thus boosting Asia Pacific market growth during the forecast period from 2018 to 2030 (Ref.).
Growth Factors:
- Increasing incidence of tick-borne encephalitis across the globe
- Growing awareness about tick-borne encephalitis and its prevention methods
- Rising demand for safe and effective vaccines against tick-borne encephalitis
- Technological advancements in vaccine development and production processes
- Growing investments by vaccine manufacturers in research and development of new Tick-borne Encephalitis Inactivated Vaccine
Scope Of The Report
Report Attributes
Report Details
Report Title
Tick-borne Encephalitis Inactivated Vaccine Market Research Report
By Type
European TBE Virus, Far Eastern TBE Virus, Siberian TBE Virus
By Application
Pediatric Vaccines, Adult Vaccines, Traveler Vaccines
By Companies
Pfizer , Encephalitis , Cochrane Collaboration, Sonic HealthPlus, Superdrug Health
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Tick-borne Encephalitis Inactivated Vaccine Market Report Segments:
The global Tick-borne Encephalitis Inactivated Vaccine market is segmented on the basis of:
Types
European TBE Virus, Far Eastern TBE Virus, Siberian TBE Virus
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pediatric Vaccines, Adult Vaccines, Traveler Vaccines
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- PfizerÂ
- EncephalitisÂ
- Cochrane Collaboration
- Sonic HealthPlus
- Superdrug Health
Highlights of The Tick-borne Encephalitis Inactivated Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- European TBE Virus
- Far Eastern TBE Virus
- Siberian TBE Virus
- By Application:
- Pediatric Vaccines
- Adult Vaccines
- Traveler Vaccines
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tick-borne Encephalitis Inactivated Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
TBEV is a vaccine that helps protect people from Tick-borne Encephalitis (TBE). TBE is a serious, life-threatening illness caused by the bite of an infected tick. Symptoms can include fever, headache, neck stiffness, and seizures. If left untreated, TBE can lead to permanent brain damage or death. The vaccine helps prevent infection with the virus that causes TBE.
Some of the key players operating in the tick-borne encephalitis inactivated vaccine market are Pfizer‚Â , Encephalitis‚Â , Cochrane Collaboration, Sonic HealthPlus, Superdrug Health.
The tick-borne encephalitis inactivated vaccine market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tick-borne Encephalitis Inactivated Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tick-borne Encephalitis Inactivated Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tick-borne Encephalitis Inactivated Vaccine Market - Supply Chain
4.5. Global Tick-borne Encephalitis Inactivated Vaccine Market Forecast
4.5.1. Tick-borne Encephalitis Inactivated Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tick-borne Encephalitis Inactivated Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tick-borne Encephalitis Inactivated Vaccine Market Absolute $ Opportunity
5. Global Tick-borne Encephalitis Inactivated Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Type
5.3.1. European TBE Virus
5.3.2. Far Eastern TBE Virus
5.3.3. Siberian TBE Virus
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tick-borne Encephalitis Inactivated Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Application
6.3.1. Pediatric Vaccines
6.3.2. Adult Vaccines
6.3.3. Traveler Vaccines
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tick-borne Encephalitis Inactivated Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tick-borne Encephalitis Inactivated Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tick-borne Encephalitis Inactivated Vaccine Demand Share Forecast, 2019-2026
9. North America Tick-borne Encephalitis Inactivated Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Application
9.4.1. Pediatric Vaccines
9.4.2. Adult Vaccines
9.4.3. Traveler Vaccines
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Type
9.7.1. European TBE Virus
9.7.2. Far Eastern TBE Virus
9.7.3. Siberian TBE Virus
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tick-borne Encephalitis Inactivated Vaccine Demand Share Forecast, 2019-2026
10. Latin America Tick-borne Encephalitis Inactivated Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Application
10.4.1. Pediatric Vaccines
10.4.2. Adult Vaccines
10.4.3. Traveler Vaccines
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Type
10.7.1. European TBE Virus
10.7.2. Far Eastern TBE Virus
10.7.3. Siberian TBE Virus
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tick-borne Encephalitis Inactivated Vaccine Demand Share Forecast, 2019-2026
11. Europe Tick-borne Encephalitis Inactivated Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Application
11.4.1. Pediatric Vaccines
11.4.2. Adult Vaccines
11.4.3. Traveler Vaccines
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Type
11.7.1. European TBE Virus
11.7.2. Far Eastern TBE Virus
11.7.3. Siberian TBE Virus
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tick-borne Encephalitis Inactivated Vaccine Demand Share, 2019-2026
12. Asia Pacific Tick-borne Encephalitis Inactivated Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Application
12.4.1. Pediatric Vaccines
12.4.2. Adult Vaccines
12.4.3. Traveler Vaccines
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Type
12.7.1. European TBE Virus
12.7.2. Far Eastern TBE Virus
12.7.3. Siberian TBE Virus
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tick-borne Encephalitis Inactivated Vaccine Demand Share, 2019-2026
13. Middle East & Africa Tick-borne Encephalitis Inactivated Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Application
13.4.1. Pediatric Vaccines
13.4.2. Adult Vaccines
13.4.3. Traveler Vaccines
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tick-borne Encephalitis Inactivated Vaccine Market Size and Volume Forecast by Type
13.7.1. European TBE Virus
13.7.2. Far Eastern TBE Virus
13.7.3. Siberian TBE Virus
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tick-borne Encephalitis Inactivated Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Tick-borne Encephalitis Inactivated Vaccine Market: Market Share Analysis
14.2. Tick-borne Encephalitis Inactivated Vaccine Distributors and Customers
14.3. Tick-borne Encephalitis Inactivated Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Encephalitis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Cochrane Collaboration
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sonic HealthPlus
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Superdrug Health
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
